A Shot of Hope: The Promising Cancer Vaccine from Merck and Moderna The latest results from a late stage trial of an experimental personalized cancer vaccine developed by Merck and Moderna have sent shockwaves through the medical community.
This treatment option has shown promising signs of effectiveness in extending the time patients live without their melanoma returning.
The Science Behind the Breakthrough The development is based on a personalized approach to immunotherapy, which targets specific mutations in each patient's tumor rather than relying on a one size fits all approach.